Is Wegovy a healthy choice? What the evidence says

What the licensing decision tells you about Wegovy's safety profile

The MHRA reviewed the full clinical data package before granting Wegovy a UK marketing authorisation for weight management. That review is not a rubber stamp: it requires evidence that benefits outweigh risks across a defined population. For Wegovy, the licensed population is adults with a BMI of at least 30, or at least 27 with a condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Approving a medicine for that group reflects a regulatory judgement that, on balance, the health gains from sustained weight reduction outweigh the known side-effect profile.

Carrying significant excess weight is itself associated with cardiovascular disease, type 2 diabetes, joint disease and reduced life expectancy. Wegovy's case rests partly on the argument that the risks of untreated obesity can exceed the risks of the medicine. That is a population-level observation, not a personal prescription — which is why clinical assessment exists. The NHS medicines page for semaglutide covers both the benefits and the side effects the MHRA expects prescribers to discuss with patients.

Wegovy also carries a Black Triangle (▼) symbol, indicating it is subject to additional monitoring by the MHRA. This is standard for newer medicines and means any new safety signals are tracked actively. It is not a warning sign, it is a transparency mechanism worth knowing about.

The side effects that shape the 'is it healthy' question

No prescription medicine is without risk, and the honest answer to whether Wegovy is healthy has to include its side-effect picture. The most common effects are gastrointestinal: nausea, vomiting, diarrhoea and constipation are reported by a significant proportion of users, particularly in the first weeks of treatment or after a dose step-up. For most people they are mild to moderate and ease once the body adjusts.

Less common but more serious effects require medical attention. Acute pancreatitis is a known risk with GLP-1 medicines: severe stomach pain that spreads to the back, especially with vomiting, calls for urgent medical assessment. Gallbladder problems have also been reported. If you experience these, contact a healthcare professional promptly rather than waiting for a scheduled review. You can report any suspected side effect, including ones not listed in the leaflet, at the MHRA's Yellow Card scheme.

There are questions the research is still answering. Long-term data beyond five years is limited because these medicines are relatively new at scale. The current evidence is compelling for the licensed period; it does not yet cover decades. A prescriber assessing your health history will weigh your personal risk factors alongside what the trials show. For a fuller picture of the conditions that may arise during treatment, our Wegovy and health issues page covers the documented risks in detail.

The cardiovascular and wider health evidence

One reason clinicians view Wegovy as a legitimate medical treatment rather than an aesthetic shortcut is the cardiovascular outcome data. The SELECT trial followed adults with established cardiovascular disease and a BMI of 27 or above (without diabetes) and found semaglutide reduced the risk of major cardiovascular events, heart attack and stroke being the primary outcomes. The MHRA granted a separate UK licence for this indication. That is meaningful: it means semaglutide is not simply associated with weight numbers falling on a scale; it is associated with events that shorten lives happening less often in clinical trials.

There is also growing evidence around mental health. Some people report improved mood, reduced anxiety around food, and a sense of control that accompanies weight loss. The relationship between semaglutide and mental health is more nuanced than simple improvement, however, and the research is ongoing, as our page on Wegovy and mental health explores in detail. Our page on semaglutide and mental health covers what the evidence currently supports. For the cardiovascular data specifically, see our explanation of how Wegovy may affect heart health.

None of this means Wegovy is healthy for everyone. Contraindications include pregnancy, breastfeeding, and a history of medullary thyroid carcinoma or MEN2. It is not licensed for under-18s. Women using oral contraceptives should be aware that semaglutide can affect gut absorption, discuss this with your prescriber before starting.

Making an informed decision with clinical support

The question of whether Wegovy is the right treatment for you is genuinely a clinical one, not one that a webpage can resolve. What this page can do is set out the evidence honestly: Wegovy is a licensed UK medicine with a regulatory-approved benefit-risk profile for a defined group, meaningful clinical trial results, and growing evidence of cardiovascular benefit. It also has real side effects, requires ongoing prescriber oversight, and is not for everyone.

If you want to understand the full range of health benefits that weight-loss treatment may bring, our overview of Wegovy's health benefits goes further. If cost is part of your thinking, the cost of Wegovy in the UK page explains what private treatment typically involves. And if you are ready to talk it through with a clinician, our prescribers at our treatment page carry out a same-day clinical review, a real person, not a queue, reads your health information the day you submit it. They can tell you whether Wegovy is clinically appropriate for you. That is the only accurate answer to this question at an individual level.